Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02045836 · ClinicalTrials.gov registry record · Phase 3

Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older

A Phase 3 study of Herpes Zoster and Herpes Zoster Vaccine, sponsored by GlaxoSmithKline.

Completed
Registry status
Phase 3
Development phase
865
Enrollment target
9
Study locations

NCT02045836 is a Phase 3 study of Herpes Zoster and Herpes Zoster Vaccine that has completed, run by GlaxoSmithKline. The registered enrollment target is 865 participants, below the 2,119-participant average among 16 other Herpes Zoster trials with a reported enrollment target (59% lower). The trial reports 9 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02045836, a Phase 3 study of Herpes Zoster and Herpes Zoster Vaccine, has completed, sponsored by GlaxoSmithKline.

COMPLETED
Registry status
Phase 3
Development phase
865 participants
Enrollment target
9
Study locations

Study Summary

The purpose of this study is to assess the immunogenicity, reactogenicity and safety of the GSK Biologicals HZ/su candidate vaccine when its first dose is co-administered with Pneumovax 23™ vaccine in adults aged 50 years or older.The impact of HZ/su vaccine on Pneumovax 23™ vaccine immune response will also be evaluated.

Conditions Studied

Herpes Zoster Herpes Zoster Vaccine

Interventions

  • BIOLOGICAL Herpes Zoster vaccine GSK 1437173A
  • BIOLOGICAL Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™

Study Locations (9)

Other

  • GSK Investigational Site - Tallinn
  • GSK Investigational Site - Tallinn
  • GSK Investigational Site - Tartu

Colorado

  • GSK Investigational Site - Golden

Kansas

  • GSK Investigational Site - Wichita

Maryland

  • GSK Investigational Site - Columbia

British Columbia

  • GSK Investigational Site - Coquitlam

Nova Scotia

  • GSK Investigational Site - Truro

Ontario

  • GSK Investigational Site - Greater Sudbury

Trial Details

FieldValue
Enrollment Target 865 participants
Start Date 2014-03-05
Est. Completion 2016-06-17
Phase Phase 3

Sponsor

GlaxoSmithKline

1,345 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02045836

The ClinicalTrials.gov registry entry for NCT02045836 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 865 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,119-participant average among 16 other Herpes Zoster trials with a reported enrollment target (59% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Herpes Zoster appearing as the primary indexed condition, and to 2 interventions - of which Herpes Zoster vaccine GSK 1437173A is the first listed.

NCT02045836 reports 9 study locations spanning 7 distinct geographic areas - top geographies include Other, Colorado, Kansas.

Frequently Asked Questions

What is clinical trial NCT02045836 about?

NCT02045836 is a clinical study titled "Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older". The purpose of this study is to assess the immunogenicity, reactogenicity and safety of the GSK Biologicals HZ/su candidate vaccine when its first dose is co-administered with Pneumovax 23™ vaccine in adults aged 50 years or older.The impact of HZ/su vaccine on Pneumovax 23™ vaccine immune response ...

What is the current status of trial NCT02045836?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 865 participants. The study started on 2014-03-05. Estimated completion is 2016-06-17.

What conditions does trial NCT02045836 study?

This clinical trial studies the following conditions: Herpes Zoster, Herpes Zoster Vaccine.

What interventions are being tested in trial NCT02045836?

The interventions under investigation include: Herpes Zoster vaccine GSK 1437173A (BIOLOGICAL), Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™ (BIOLOGICAL).

Who is sponsoring clinical trial NCT02045836?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02045836 being conducted?

This trial has 9 study locations across Colorado, Kansas, Maryland, British Columbia, Nova Scotia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Herpes Zoster

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Herpes Zoster

All registered trials for this condition

Herpes Zoster Vaccine

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.